UCB's Global Corporate Website

UCB research partner wins Life Sciences Breakthrough Prize

Posted by
Laurent Schots, Global Communications & Company Reputation
Professor Huda Zoghbi has been awarded the $3 million ‘Breakthrough Prize’ in Life Sciences at a red-carpet ceremony in San Francisco for her ground-breaking genetic research.

Professor Zoghbi is one of our valued research partners and leads a strategic research programme at Baylor College of Medicine in the US. Together we are exploring how the exciting area of functional genetics can be harnessed to identify therapeutic targets for new medicines. Her team, in collaboration with our researchers, aims to discover medicines based on genetically validated targets that could transform the lives of people living with severe neurodegenerative diseases.

The Breakthrough Prize ceremony – sometimes called ‘The Oscars of Science’ – is well attended, attracting a host of celebrities, philanthropists and researchers. The prize was founded in 2013 by Sergey Brin and Anne Wojcicki of Google, Mark Zuckerberg and Priscilla Chan of Facebook, Yuri Julia Milner of Digital Sky Technologies, and Jack Ma and Cathy Zhang of Alibaba.

More than $25 million is awarded to excellent scientists whose work is making a real difference to humankind. The life sciences prize honours transformative advances towards understanding living systems and extending human life. Professor Zoghbi was recognised for discoveries of the genetic causes and mechanisms of spinocerebellar ataxia and Rett syndrome. She is now using the same approach to study Parkinson’s and Alzheimer’s disease.

UCB is pleased to see this work recognised at the highest level. It reflects our commitment to work with world-class researchers in pursuit of progress in medical science. We will continue to collaborate with top scientists who share our desire to improve the lives of people with severe diseases.

Leave a Comment

By submitting your personal data, you agree with UCB's Data Privacy Policy. Furthermore, for more information on the terms of use of this website please visit our Legal Notice, accessible here.